Comparison of clinical outcomes of drug-coated balloon treatment for in-stent restenosis with different clinical presentations
10.3969/j.issn.1004-8812.2025.11.006
- VernacularTitle:药物涂层球囊治疗不同临床表现支架内再狭窄的临床结局比较
- Author:
Hui-fang ZHANG
1
;
Hong-yong SONG
;
Guo LI
;
Dong-fang HE
;
Qian TAO
Author Information
1. 首都医科大学附属北京安贞医院心血管内科,北京 100029
- Publication Type:Journal Article
- Keywords:
Drug-coated balloon;
In stent restenosis;
Acute coronary syndrome;
Clinical presentation;
Clinical outcomes
- From:
Chinese Journal of Interventional Cardiology
2025;33(11):640-646
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical outcomes of patients with coronary in-stent restenosis(ISR)who underwent drug-coated balloon(DCB)treatment,based on different clinical presentations.Methods This prospective study included 508 patients diagnosed with coronary ISR at Anzhen Hospital,Capital Medical University,between May 2020 and May 2022.All patients received DCB treatment.According to clinical presentation,the patients were divided into an acute coronary syndrome(ACS)group(185 patients)and a non-acute coronary syndrome(non-ACS)group(323 patients).All patients were followed for two years,primarily comparing the incidence of myocardial infarction(MI),target lesion revascularization(TLR),death,and major adverse cardiovascular events(MACE)between the two groups.Results Baseline data showed that the ACS group had a significantly higher proportion of hypertension,diabetes,and smoking compared to the non-ACS group(all P＜0.05).Additionally,the ACS group had a higher proportion of B2/C-type lesions,long lesions,and moderate to severe calcified lesions(all P＜0.05).The number,length,and diameter of stents implanted were also significantly larger in the ACS group(all P＞0.05).At the 1-year follow-up,the ACS group had a significantly higher incidence of TLR(8.1％vs.2.5％,P=0.007)and MACE(10.3％vs.5.3％,P=0.047)than the non-ACS group.By the end of the 2-year follow-up,the ACS group still had higher rates of TLR(18.9％vs.10.2％,P=0.007)and MACE(22.7％vs.14.9％,P=0.030).Conclusions ISR patients with ACS have higher cardiovascular risk and more complex lesions.They also experience a higher incidence of adverse events after DCB treatment.
